Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Filings indexed 1,095 across all filing types
Latest filing 2021-05-10 Interim / Quarterly Rep…
Country US United States of America
Listing US NVAX

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2021
2021-05-10 English
FORM 4 SUBMISSION
Director's Dealing
2021-05-07 English
FORM 4 SUBMISSION
Director's Dealing
2021-05-04 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically labeled as a Definitive Additional Materials for the 2021 Annual Meeting of Novavax, Inc. It includes voting items such as election of directors, advisory approval of executive compensation, stock plan amendments, and ratification of equity awards and auditor appointment. This type of document is used to solicit shareholder votes and provide information related to the annual meeting. It is not the annual report itself, nor a report publication announcement, but proxy solicitation materials. According to the filing definitions, proxy solicitation materials correspond to the category 'Proxy Solicitation & Information Statement' (PSI). The document length is 4887 characters, which is consistent with a proxy statement or related materials. Therefore, the correct classification is PSI with high confidence.
2021-05-03 English
DEF 14A
Proxy Solicitation & Information Statement
2021-05-03 English
FORM 10-K/A
Annual Report FY 2020
2021-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.